Regeneron has the right to license resulting antibodies for therapeutic or diagnostic use.

Columbia University Medical Center has gained access to Regeneron’s VelocImmune® technology to discovery fully human mAbs. The research will look for potential human therapeutics based on the antibodies generated from VelocImmune mice against their research targets.

Regeneron has an exclusive option to license the antibodies for development and commercialization as therapeutic or diagnostic products.

 “VelocImmune is the only antibody platform that allows researchers with limited antibody production resources to create high affinity, well-expressing, fully human antibodies in their own laboratories,” according to George D. Yancopoulos, M.D., Ph.D., president of Regeneron.

Previous articleSequenom Bolsters IP Position in Prenatal Testing through Deal with the Chinese University of Hong Kong
Next articleCytokinetics Lets Go of Oncology Research Business and 29% of Staff